Fusion Pharmaceuticals Inc. Common Shares
FUSN
FUSN was delisted on the 3rd of June, 2024.
28 hedge funds and large institutions have $219M invested in Fusion Pharmaceuticals Inc. Common Shares in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
89% more capital invested
Capital invested by funds: $116M → $219M (+$103M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
13% less funds holding
Funds holding: 32 → 28 (-4)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$10.7M |
| 2 |
Morgan Stanley
New York
|
+$191K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$154K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$151K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.07M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$1.58M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$484K |
| 4 |
E
Ergoteles
New York
|
-$46K |
| 5 |
BlackRock
New York
|
-$9.43K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $7K | – | – | – |
|
|
S
27
SignatureFD
Atlanta,
Georgia
| $2K | – | – | – |
|
|
APA
28
American Portfolios Advisors
Holbrook,
New York
| $233 | – | – | – |
|
|
E
29
Ergoteles
New York
| – | -$46K | -11,000 | Closed |
|
30
Bank Julius Baer & Co
Zurich,
Switzerland
| – | -$8K | -2,000 | Closed |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | -$5K | -1,160 | Closed |
|
FUSN Hedge Fund Activity: Q1 2022 in Review
28 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q1 2022, worth a combined $219M — up 89% from $116M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of FUSN and 0 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Federated Hermes, adding an estimated $10.7M. The largest seller was Point72 Asset Management, cutting an estimated $5.07M.
- 28 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q1 2022, down from 32 in Q4 2021.
- Funds reported $219M of Fusion Pharmaceuticals Inc. Common Shares stock for Q1 2022, up 89% quarter-over-quarter.
- 0 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q1 2022 and 3 closed out, a net change of -3 holders.
- The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q1 2022 was Federated Hermes, an estimated $10.7M added.
- The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q1 2022 was Point72 Asset Management, an estimated $5.07M sold.
Based on aggregated 13F filings for Q1 2022.